Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma

Hepatology

Volumn 61, Issue 3, 2015, Pages 930-941

  Reichl, Patrick ^a   Dengler, Mirko ^a   van Zijl, Franziska ^a   Huber, Heidemarie ^a   Führlinger, Gerhard ^a   Reichel, Christian ^b   Sieghart, Wolfgang ^c   Peck Radosavljevic, Markus ^c   Grubinger, Markus ^a   Mikulits, Wolfgang ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Doping Control Laboratory   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE AXL; SMAD3 PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN 14 3 3; YWHAZ PROTEIN, HUMAN;

ARTICLE; CELL INVASION; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GROWTH INHIBITION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TUMOR RECURRENCE; UPREGULATION; AUTOCRINE EFFECT; CELL MOTION; LIVER TUMOR; MORTALITY; PATHOLOGY; PHYSIOLOGY; TUMOR INVASION;

14-3-3 PROTEINS; AUTOCRINE COMMUNICATION; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84923296070     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27492     Document Type: Article

References (31)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
3. Reichl P, Haider C, Grubinger M, Mikulits W. TGF-beta in epithelial to mesenchymal transition and metastasis of liver carcinoma. Curr Pharm Des 2012;18:4135-4147.
4. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-890.
5. Giannelli G, Villa E, Lahn M. Transforming growth factor-beta as a therapeutic target in hepatocellular carcinoma. Cancer Res 2014;74:1890-1894.
6. Massague J. TGFbeta in cancer. Cell 2008;134:215-230.
7. Heldin CH, Moustakas A. Role of Smads in TGFbeta signaling. Cell Tissue Res 2012;347:21-36.
8. Matsuzaki K. Modulation of TGF-beta signaling during progression of chronic liver diseases. Front Biosci (Landmark Ed) 2009;14:2923-2934.
9. Zulehner G, Mikula M, Schneller D, van Zijl F, Huber H, Sieghart W, et al. Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. Am J Pathol 2010;176:472-481.
10. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014;15:178-196.
11. Mori S, Matsuzaki K, Yoshida K, Furukawa F, Tahashi Y, Yamagata H, et al. TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 2004;23:7416-7429.
12. Murillo MM, del Castillo G, Sanchez A, Fernandez M, Fabregat I. Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes. Oncogene 2005;24:4580-4587.
13. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol 2008;8:327-336.
14. Lemke G. Biology of the TAM receptors. Cold Spring Harb Perspect Biol 2013;5:a009076.
15. Tsou AP, Wu KM, Tsen TY, Chi CW, Chiu JH, Lui WY, et al. Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics 1998;50:331-340.
16. Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 2011;30:1229-1240.
17. Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 2010;107:1124-1129.
18. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 2008;68:1905-1915.
19. Aitken A. Post-translational modification of 14-3-3 isoforms and regulation of cellular function. Semin Cell Dev Biol 2011;22:673-680.
20. Choi JE, Hur W, Jung CK, Piao LS, Lyoo K, Hong SW, et al. Silencing of 14-3-3zeta over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium. Cancer Lett 2011;303:99-107.
21. Huang XY, Ke AW, Shi GM, Zhang X, Zhang C, Shi YH, et al. alphaB-crystallin complexes with 14-3-3zeta to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma. Hepatology 2013;57:2235-2247.
22. van Zijl F, Mall S, Machat G, Pirker C, Zeillinger R, Weinhaeusel A, et al. A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. Mol Cancer Ther 2011;10:850-860.
23. Lee HJ, Jeng YM, Chen YL, Chung L, Yuan RH. Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma. Carcinogenesis 2014;35:769-775.
24. Bauer T, Zagorska A, Jurkin J, Yasmin N, Koffel R, Richter S, et al. Identification of Axl as a downstream effector of TGF-beta1 during Langerhans cell differentiation and epidermal homeostasis. J Exp Med 2012;209:2033-2047.
25. Kim SH, Ahn S, Park CK. Smad3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy. Hepatobil Pancreat Dis Int 2012;11:51-59.
26. Matsuzaki K. Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis 2011;32:1578-1588.
27. Tarasewicz E, Jeruss JS. Phospho-specific Smad3 signaling: impact on breast oncogenesis. Cell Cycle 2012;11:2443-2451.
28. Hong HY, Jeon WK, Bae EJ, Kim ST, Lee HJ, Kim SJ, et al. 14-3-3 sigma and 14-3-3 zeta plays an opposite role in cell growth inhibition mediated by transforming growth factor-beta 1. Mol Cells 2010;29:305-309.
29. Obsil T, Obsilova V. Structural basis of 14-3-3 protein functions. Semin Cell Dev Biol 2011;22:663-672.
30. Korshunov VA. Axl-dependent signalling: a clinical update. Clin Sci (Lond) 2012;122:361-368.
31. Matsuzaki K, Seki T, Okazaki K. TGF-beta signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases. J Gastroenterol 2014;49:971-981.